Results 111 to 120 of about 3,981,458 (213)

Unsupervised Global CBC/RUO/CPD Phenotyping Identifies Haematological Clusters Enriched for Thrombocytopenia Severity and Mechanisms

International Journal of Laboratory Hematology, Volume 48, Issue 6, Page 1385-1395, December 2026.
ABSTRACT Introduction Thrombocytopenia has heterogeneous mechanisms, including peripheral destruction, consumption, and reduced marrow production. This study developed an unsupervised global complete blood count/research‐use‐only/cell population data (CBC/RUO/CPD) phenotyping model and evaluated post hoc whether thrombocytopenia severity and clinically
Mohammad A. Altememi, Emmanuel J. Favaloro, Md Zahidul Islam, Sara Ng, Danny Hsu, Abishek B. Santhakumar   +5 more
wiley   +1 more source

Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions

Cancer, Volume 132, Issue 22, 15 November 2026.
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato, Gloria Cocchetto, Simona Barbato, Michele Puppi, Simone Masci, Elena Zamagni   +5 more
wiley   +1 more source

Mechanism of Fruit Ethanol Extract of Phoenix dactylifera on Heparin Induced Thrombocytopenia in Rats [PDF]

, 2016
Thrombocytopenia occurs frequently in patients with hematologic disorders and other diseases in hospital. Thrombocytopenia may cause bleeding, from mild to severe, which is treated for the patients.
Riami, Ita Rahmawati, Roihatul Zahroh, Harjanto JM, Junaidi Khotib, NIDN. 0022107001   +4 more
core   +2 more sources

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, Volume 159, Issue 10, Page 2552-2561, 15 November 2026.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

Dose escalation study of an anti- thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia

, 2020
Background: Preclinical studies demonstrated that small chain RNA fragments accelerate the recovery of platelets numbers in animals exposed to high doses of chemotherapeutic drugs. There is anecdotal data supporting the same application in humans.
Digant Gupta, Christopher G Lis, Maryann Daehler, Robert D Levin, John L Hall, James F Grutsch   +5 more
core   +1 more source

Chemotherapy-Induced Hematological Toxicity in Patients with Renal or Hepatic Impairment

Pharmaceutics
Background/Objectives: Hematological toxicities (i.e., neutropenia, thrombocytopenia, and anemia), are common chemotherapy complications and may be exacerbated by renal or hepatic impairment due to altered drug exposure.
Kelly Nies, Robin Vernooij, Lot Devriese, Jan-Hendrik Venhuizen, Maarten ten Berg, Christina Swart, Laureen Lammers, Saskia Haitjema   +7 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, Volume 20, Issue 11, Page 2584-2610, November 2026.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Successful Remission of Hemolytic-Uremic Syndrome during the Third-line Weekly Gemcitabine for Metastatic Breast Cancer

Breast Cancer: Basic and Clinical Research, 2014
Sequential palliative chemotherapy for metastatic breast cancer incorporating weekly gemcitabine administered as three-weeks-on, one-week-off schedule is widely adopted throughout the East Asia region.
Victor C. Kok, Sheng-Chung Wu, Chien-Kuang Lee   +2 more
doaj   +1 more source

Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3‐Mutated AML: The PETHRATIFY Study

American Journal of Hematology, Volume 101, Issue 11, Page 2812-2826, November 2026.
ABSTRACT Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.
Mónica Alejandra Romero Riquelme, Gaspar Aspas Requena, Pilar Lloret‐Madrid, Cristina Gil, Eliana Aguiar, Mar Tormo, Teresa del Bernal del Castillo, Eduardo Rodríguez Arbolí, Josefina Serrano, Joaquín Sánchez‐García, Carlos Rodríguez‐Medina, José Mário Mariz, Rosa Ayala, Joaquín Martínez‐López, María Luz Amigo, Susana Vives, Lorenzo Algarra Algarra, Raimundo García Boyero, Joana Brioso, Tamara Castaño, Juan M. Bergua Burgués, Olga Salamero, María Francisca Bass Maturana, Mercedes Colorado, María García Fortes, María José Sayas Lloris, Belén Vidriales Vicente, Carmen Chillón, Esther Pérez Santaolalla, María Dolores Madrigal, Jorge Labrador Gómez, María José García Pérez, Soledad Casado Calderón, Manuel Pérez Encinas, Amaia Balerdi Malcorra, María Solé Rodríguez, Lara María Gómez García, Pilar Herrera Puente, Olga Arce Fernández, Manuel Barrios García, Víctor Noriega, Rosa Fernández, Mamen Mateos, Carolina Lacalzada, Ágata Almela Gallego, María Carmen García Garay, Carmen Couto, José Antonio Pérez‐Simón, Eva Barragán González, Pau Montesinos   +49 more
wiley   +1 more source

Real‐World Validation of the MAGIC‐D Index in Unresectable Biliary Tract Cancer Treated With Durvalumab Plus Chemotherapy

Cancer Medicine, Volume 15, Issue 11, November 2026.
Real‐world Validation of the MAGIC‐D Index. The MAGIC‐D index was validated using real‐world data from patients with unresectable BTC who received durvalumab‐chemotherapy at Tongji Hospital. The risk stratification ability of the MAGIC‐D index for patient survival was improved after incorporating Ki67 and CA 19‐9.
Tianao Zhan, Hongwei Huang, Juncheng Zhan, Feng Xia, Tianyin Shao, Xinkang Liu, Jun Shen, Xingbin Xu, Yawei Fan, Qi Cheng   +9 more
wiley   +1 more source